 |
5 Diseases |  |
0 Trials |
|
0 Trials |  |
5 News |  |
- || S-707106 / Shionogi
Clinical, P1/2 data, Journal: An open-label phase Ⅰ/Ⅱ a clinical trial of 11β-HSD1 inhibitor for Cushing's syndrome and autonomous cortisol secretion. (Pubmed Central) - Dec 16, 2021
S-707106 is an effective insulin sensitizer and anti-sarcopenic and anti-obesity medication for these patients.
- S-707106 / Shionogi
Phase classification, Combination therapy: Study to Assess Safety and Pharmacokinetics of Double-Blind S-707106 Alone and in Combination With Open-Label Metformin in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Apr 27, 2018
P1b, N=34, Completed, Sponsor: Shionogi
S-707106 is an effective insulin sensitizer and anti-sarcopenic and anti-obesity medication for these patients. Phase classification: P1 --> P1b
- ||| S-707106 / Shionogi
Enrollment change: Safety and Efficacy of S-707106 in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control With Metformin Therapy (clinicaltrials.gov) - Apr 8, 2013
P2, N=218, Completed, Sponsor: Shionogi
Phase classification: P1 --> P1b N=280 --> 218
- |||| S-707106 / Shionogi
Trial completion: Safety and Efficacy of S-707106 in Subjects With Type 2 Diabetes Mellitus and Inadequate Glycemic Control With Metformin Therapy (clinicaltrials.gov) - Apr 8, 2013
P2, N=218, Completed, Sponsor: Shionogi
N=280 --> 218 Active, not recruiting --> Completed
- | S-707106 / Shionogi
Trial completion, Combination therapy: Study to Assess Safety and Pharmacokinetics of Double-Blind S-707106 Alone and in Combination With Open-Label Metformin in Patients With Type 2 Diabetes Mellitus (clinicaltrials.gov) - Sep 12, 2011
P1, N=34, Completed, Sponsor: Shionogi
Active, not recruiting --> Completed Recruiting --> Completed